Fig. 5
From: Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells
Effects of cotreatments on vorinostat-regulated signaling molecules in SCLC cells. a H209 and b H146 cells were treated with indicated concentrations of vorinostat (0.1, 0.25, and 0.5 μM and 0.05, 0.1, and 0.2 μM, respectively), cisplatin alone (5 μM), and a combination of these 2 agents for 24 h. Cell lysates were collected and subjected to Western blot analysis with acetyl α-tubulin, acetyl histone H3, TS, and β-actin